<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">Молодежный инновационный вестник</journal-id><journal-title-group><journal-title>Молодежный инновационный вестник</journal-title></journal-title-group><issn publication-format="print">2415-7805</issn><publisher><publisher-name>Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">11367</article-id><article-categories><subj-group subj-group-type="heading"><subject>Conference Proceedings</subject></subj-group></article-categories><title-group><article-title>Evaluation of the effectiveness of gemcitabine chemotherapy (Gemzar) in patients with pancreatic cancer: a retrospective analysis of the dynamics of tumor markers and the size of the primary focus</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Manya</surname><given-names>Vladislav Valeryevich</given-names></name><bio>&lt;p&gt;Student&lt;/p&gt;</bio><email>vladislav.manya@yandex.ru</email><uri content-type="orcid">https://orcid.org/0009-0009-4110-8484</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Medvedev</surname><given-names>Dmitry Mikhailovich</given-names></name><bio>&lt;p&gt;Student&lt;/p&gt;</bio><email>medvedevdmitrii04@mail.ru</email><uri content-type="orcid">https://orcid.org/0009-0005-1290-8440</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Borisov</surname><given-names>Vladimir Alexandrovich</given-names></name><email>borisov_2002@mail.ru</email><uri content-type="orcid">https://orcid.org/0000-0002-6175-7336</uri><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">Burdenko Voronezh State Medical University</aff><pub-date date-type="epub" iso-8601-date="2026-10-01" publication-format="electronic"><day>01</day><month>10</month><year>2026</year></pub-date><volume>15</volume><issue>S1</issue><fpage>579</fpage><lpage>581</lpage><history><pub-date date-type="received" iso-8601-date="2026-02-28"><day>28</day><month>02</month><year>2026</year></pub-date><pub-date date-type="accepted" iso-8601-date="2026-03-26"><day>26</day><month>03</month><year>2026</year></pub-date></history><permissions><copyright-statement>Copyright © 2026, Manya V.V., Medvedev D.M., Borisov V.A.</copyright-statement><copyright-year>2026</copyright-year></permissions><abstract>&lt;p style="text-align: justify;"&gt;Pancreatic cancer (PC) holds a special place in the structure of cancer morbidity due to its extremely unfavorable prognosis, demonstrating a steady upward trend in incidence and very high mortality rates. Despite technological advances in surgery and drug therapy, the five-year survival rate for this cancer type does not exceed 10%, and in countries with limited healthcare resources, this figure remains even lower. Such disappointing results are directly correlated with late diagnosis; in more than 80% of cases, the disease is detected at stages IIIIV, when the neoplasm loses resectability, thus precluding the possibility of radical intervention. Instrumental diagnostic methods (CT, MRI, ultrasound) have high accuracy only when the tumor is already formed, which limits their use for early screening of individuals at increased risk. Serological markers, particularly CA 19‑9, which has remained the "gold standard" for decades, serve to monitor treatment effectiveness for pancreatic, gastric, or biliary tract cancer. A decrease in its level indicates effective therapy, while an increase suggests progression or recurrence. Suspicion of pancreatic cancer arises when symptoms are present (jaundice, abdominal pain, weight loss) in conjunction with other diagnostic methods (ultrasound, CT). Early detection of recurrences after radical treatment (surgery) in patients is possible by monitoring the rise in CA 19-9 levels. Objective. To systematize and critically analyze modern methods of diagnosis and treatment of pancreatic cancer, evaluate their effectiveness, and study the side effects of the drug in patients who underwent treatment at the Lipetsk Regional Oncology Clinic. Materials and Methods. The study was conducted based on a retrospective review of inpatient medical records at the Lipetsk Regional Oncology Clinic. A total of 16 individuals with pancreatic cancer were examined. Patients underwent instrumental and laboratory tests before and after chemotherapy (the primary drug was Gemzar). Indicators such as tumor size, CA 19-9 tumor marker, and TNM stage were assessed.&lt;/p&gt;</abstract><kwd-group xml:lang="en"><kwd>Pancreatic cancer</kwd><kwd>Gemcitabine (Gemzar)</kwd><kwd>chemotherapy</kwd><kwd>CA 19-9</kwd><kwd>computed tomography</kwd><kwd>treatment effectiveness</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак поджелудочной железы</kwd><kwd>Гемцитабин (Гемзар)</kwd><kwd>химиотерапия</kwd><kwd>СА 19-9</kwd><kwd>компьютерная томография</kwd><kwd>эффективность лечения</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72(1):7-33.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2021;19(4):439-457.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Annals of Oncology. 2022;21(3):441-447.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. European Journal of Pharmacology. 2022;741:8-16.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology. 2022;15(6):2403-2413.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer. 2022;45(2):228-247.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Покатаев И.А., Трякин А.А., Бредер В.В. и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2022;11(3s2):390-405.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine. 2022;369(18):1691-1703.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine. 2023;364(19):1817-1825.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022.</mixed-citation></ref></ref-list></back></article>
